Trials / Active Not Recruiting
Active Not RecruitingNCT04549207
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
A Randomised Trial Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer (REaCT-Hold BMA)
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Ottawa Hospital Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators propose to perform a pragmatic, multicenter, open-label, randomised clinical trial to demonstrate the efficacy and safety of either continuing or further de-escalating BMA after a minimum of two years of BMA treatment in patients with bone metastases from breast cancer and castration-resistant prostate cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bone modifying agent | Use of bone modifying agent |
Timeline
- Start date
- 2020-10-09
- Primary completion
- 2025-04-17
- Completion
- 2026-06-01
- First posted
- 2020-09-16
- Last updated
- 2026-04-07
Locations
5 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT04549207. Inclusion in this directory is not an endorsement.